KalVista amends CFO employment agreement raising base salary to $565K; updates bylaws for universal proxy rules

KalVista Pharmaceuticals, Inc.

CFO Benjamin L. Palleiko's base salary raised to $565,000 (effective May 1, 2023); target bonus increased to 50% of salary.
Severance: 15 months base salary and COBRA if terminated without cause/for good reason before Change in Control.
If terminated within 2 years after Change in Control: 21 months base salary, full target bonus, full equity vesting, COBRA.
Bylaws amended for DGCL updates, universal proxy rules, and exclusive forum (Delaware Chancery Court).

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

KalVista Pharmaceuticals, Inc.: Adopted amended and restated bylaws effective June 14, 2023, incorporating changes related to universal proxy rules, recent DGCL amendments, and other governance updates (effective 2023-06-14).

Change: bylaw amendment
Effective: 2023-06-14

Exact text from the filing

On June 14, 2023, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “ DGCL ”), and a periodic review of the bylaws of KalVista Pharmaceuticals, Inc. (the “ Company ”), the Company’s board of directors (the “ Board ”) approved and adopted the Company’s amended and restated bylaws (the “ Amended and Restated Bylaws ”), which became immediately effective.

View on SEC.gov

Browse all governance changes →

KalVista Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-027974

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.